KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neogenomics (NEO) Gross Profit: 2009-2024

Historic Gross Profit for Neogenomics (NEO) over the last 16 years, with Dec 2024 value amounting to $290.1 million.

  • Neogenomics' Gross Profit rose 7.43% to $80.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $308.2 million, marking a year-over-year increase of 9.90%. This contributed to the annual value of $290.1 million for FY2024, which is 18.60% up from last year.
  • Neogenomics' Gross Profit amounted to $290.1 million in FY2024, which was up 18.60% from $244.6 million recorded in FY2023.
  • In the past 5 years, Neogenomics' Gross Profit ranged from a high of $290.1 million in FY2024 and a low of $185.9 million during FY2020.
  • Over the past 3 years, Neogenomics' median Gross Profit value was $244.6 million (recorded in 2023), while the average stood at $240.9 million.
  • As far as peak fluctuations go, Neogenomics' Gross Profit dropped by 5.56% in 2020, and later spiked by 30.18% in 2023.
  • Neogenomics' Gross Profit (Yearly) stood at $185.9 million in 2020, then grew by 0.63% to $187.1 million in 2021, then increased by 0.45% to $187.9 million in 2022, then surged by 30.18% to $244.6 million in 2023, then climbed by 18.60% to $290.1 million in 2024.